Skip to main content

LCD L38968: Thyroid Nodule Molecular Testing

LCD L38968, Thyroid Nodule Molecular Testing, is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2021-12-01. The policy text runs 157 words, and its billing and coding article A58656 lists 10 ICD-10-CM codes that support medical necessity for 4 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2021-12-01
Policy text
157 words
Covered ICD-10 codes (articles)
10

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38968
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A58656: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A58656 (Billing and Coding: Thyroid Nodule Molecular Testing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A58656: Billing and Coding: Thyroid Nodule Molecular Testing (Billing and Coding, effective 2026-04-01)

Covered ICD-10-CM codes
10
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
4
Full article
cms.gov record
First 10 covered ICD-10-CM codes in A58656
ICD-10-CMDescription (FY2027)
D44.0Neoplasm of uncertain behavior of thyroid gland
D44.9Neoplasm of uncertain behavior of unspecified endocrine gland
E01.0Iodine-deficiency related diffuse (endemic) goiter
E01.1Iodine-deficiency related multinodular (endemic) goiter
E01.2Iodine-deficiency related (endemic) goiter, unspecified
E04.0Nontoxic diffuse goiter
E04.1Nontoxic single thyroid nodule
E04.2Nontoxic multinodular goiter
E04.8Other specified nontoxic goiter
E04.9Nontoxic goiter, unspecified

Procedure codes: 0018U, 0026U, 81546, 81599.

Coverage indications, limitations and medical necessity

Indications and Limitations of Coverage

The use of molecular testing (MT)* to assess thyroid nodules may be considered medically necessary ONCE per nodule workup when ALL of the following criteria are met:

• Thyroid fine-needle aspiration (s) (FNA) performed secondary to established indications based on ultrasound characteristics, size and clinical findings (1)

• Presence of indeterminate thyroid FNA cytopathology described as (1,2)

• Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS) (i.e., Bethesda category III), or

• Follicular neoplasm (FN) or suspicious for a follicular neoplasm (SFN) (i.e., Bethesda category IV)

• The need for thyroidectomy is unclear after consideration of clinical, imaging, and cytologic features (1,2)

• Local institutional malignancy rates are known and used for optimal extrapolation of results to thyroid cancer risk (1)

• Informed patient willing to potentially undertake surveillance (1)

*The scope of this LCD is limited to tests submitted on claims to NGS jurisdictions J6 and JK.

Summary of evidence (opening)

Thyroid cancer is the most common endocrine malignancy, with over fifty thousand new United States diagnoses in 2020 (3). Thyroid nodules are exceedingly common with prevalence rates of up to 68%, with higher frequencies in the elderly (4). While the majority (85-93%) of thyroid nodules are benign, diagnostic testing (history and physical, laryngoscopy, hormone and chemistry analysis, ultrasound, CT, FNA, and surgical excision) is required to confirm. Over 600,000 thyroid FNAs are performed every year in the United States, and the number has been increasing annually by 16% (5). Despite this diagnostic gauntlet, approximately 20% of FNA results are classified indeterminate (Bethesda III/IV) with a 10-40% risk of malignancy (6). Cancer rates vary widely by institution, ranging from 6-48% for Bethesda III and 14-34% for Bethesda IV. Repeat FNA of Bethesda III nodules should be strongly considered as it leads to a more definitive reclassification in 60-65% (1). Previously, the majority of patients with an indeterminate FNA, confirmed on repeat aspiration, had diagnostic thyroid surgery (usually lobectomy), with most (75-95%) ultimately confirmed to be benign (6). Rates of thyroid surgery-specific postoperative complications (recurrent laryngeal nerve injury, permanent hypoparathyroidism, and postoperative hematoma) in high-volume institution studies range between 0.4-7.4%, but a population-based study found it as high as 12.3% (7).

In 2012, molecular marker testing (MT) became widely available as a potential method to augment risk stratification of indeterminate FNA results, ideally reducing the need for diagnostic thyroid surgery or completion thyroidectomy, with their attendant risks and costs. A patient with a low MT malignancy risk is potentially recommended for surveillance with serial ultrasounds to ensure nodule stability. Conversely, a high malignancy MT result could strengthen a recommendation to move forward with surgical removal ( lobectomy or total thyroidectomy ). Molecular profiling includes genomic alterations (such as point mutations, insertions, and deletions), gene fusions resulting in rearrangements or translocations, copy number variations, RNA-based gene expression, and/or micro-RNA (miRNA) expression (1).

In 2016, the nomenclature of encapsulated follicular variant of papillary thyroid cancer was changed to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in recognition of its highly indolent nature. Thus, the value of MT may arise both from the avoidance of surgery and the fact that surveillance is now a safer and more informed option (8). Conversely, given clinical guideline recognition that more limited cancer operation can lead to equivalent outcomes, the impact of molecular testing in directing the extent of surgical resection is diminished (9).

Thyroseqv3 (CBLPath, Inc.; Rye Brook, NY)

The contractor cites 18 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2021-12-01
Current revision effective
2026-04-01
Last reviewed by the contractor
2021-07-01
MCD version
5

The contractor lists 2 National Coverage Determinations as related: NCD 190.22 Thyroid Testing, NCD 90.2 Next Generation Sequencing (NGS). Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A58853 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38968 cover?

The use of molecular testing (MT)* to assess thyroid nodules may be considered medically necessary ONCE per nodule workup when ALL of the following criteria are met: The full 157-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38968 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38968?

The companion billing and coding article A58656 lists 10 ICD-10-CM codes in 1 group that support medical necessity; the first 10 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L38968?

A denial under LCD L38968 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A58656's 10 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.